| 英文别名 |
Linsitinib;OSI-906 (Linsitinib);OSI 906;cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol;OSI-906AA;3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol;Cyclobutanol, 3-[8-amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl-, cis-;Linsitinib (OSI-906, OSI 906AA);Linsitinib(OSI906);OSI-906;OSI-906 Linsitinib;cis-3-(8-amino-1-(2-phenyl-7-quinolinyl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol;cis-3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-1-yl]-1-methylcyclobutan-1-ol;cis-3-[8-amino-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol;Kinome_3532;OSI906;15A52GPT8T;MMV676605;C26H23N5O;3-[8-amino-1-(2-phenyl-7-quinolinyl)-3-imidazo[1,5-a]pyrazinyl]-1-methyl-1-cyclobutanol;cis-3-(8-amino-1-(2-phenyl-7-quinolinyl)imidazo(1,5-a)py;cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol (ACI);OSI 906AA;Cis-3-(8-Amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutan-1-ol;HY-10191;trans-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol;CHEBI:91402;NCGC00250375-11;SCHEMBL10255925;DTXSID401007055;MFCD12912153;DTXSID901121553;(1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutan-1-ol;Q6554803;LINSITINIB [WHO-DD];3-(8-amino-1-(2-phenylquinolin-7-yl)-2,3-dihydroimidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol;NS00073285;BCP01831;MLS006010304;BRD-K86118762-001-01-8;AKOS024464740;NCGC00250375-02;LINSITINIB [INN];Linsitinib [USAN:INN];SW218150-2;SDCCGSBI-0646932.P001;DB06075;CIS-3-(8-AMINO-1-(2-PHENYLQUINOLIN-7-YL)IMIDAZO(1,5-A)PYRAZIN-3-YL)-1-METHYLCYCLOBUTAN-1-OL;Linsitinib (USAN/INN);CCG-264815;NCGC00250375-03;s1091;NSC800784;HMS3654C19;SCHEMBL400369;CYCLOBUTANOL, 3-(8-AMINO-1-(2-PHENYL-7-QUINOLINYL)IMIDAZO(1,5-A)PYRAZIN-3-YL)-1-METHYL-, CIS-;D09925;AC-26953;NSC-756652;GTPL7423;Linsitinib [USAN];(1R,3S)-3-[8-AMINO-1-(2-PHENYLQUINOLIN-7-YL)IMIDAZO[1,5-A]PYRAZIN-3-YL]-1-METHYLCYCLOBUTAN-1-OL;SR-05000022538;(1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol;SCHEMBL400734;NSC756652;CS-0242;1356958-77-4;BRD-K86118762-001-05-9;SMR004700744;AS-16999;(1r,3r)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol.;SCHEMBL400735;867160-71-2;BDBM50315887;EX-A719;BDBM185150;CHEMBL1091644;J-520074;BCP9001035;Linsitinib(OSI-906)?;UNII-15A52GPT8T;Linsitinib; OSI-906;PB22643;Linsitinib(OSI-906);cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol; OSI 906; OSI 906AA;;CHEMBL1996234;BCPP000137;Q27163260;BRD-K07667918-001-01-3;867160-72-3;NCGC00250375-14;Linsitinib (OSI-906);cis-3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol;HMS3295G15;NSC-800784;3-[8-AMINO-1-(2-P... |